scholarly journals Decreased 5'-nucleotidase activity in a T lymphocyte subpopulation from patients with B cell chronic lymphocytic leukemia

Blood ◽  
1984 ◽  
Vol 64 (2) ◽  
pp. 479-481
Author(s):  
R Silber ◽  
M Conklyn
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
T Lymphocyte ◽  
Specific Activity ◽  
Normal Subjects ◽  
Lymphocyte Subpopulation ◽  
Lymphocytic Leukemia ◽  
Nucleotidase Activity ◽  
T Lymphocyte Subpopulations ◽  
Low Activity

The activity of the ectoenzyme 5′-nucleotidase (5′N) was determined in the T lymphocyte subpopulations from patients with chronic lymphocytic leukemia (CLL). 5′N could be detected only in the T cells from patients whose B cells also had enzyme activity. The specific activity of CLL T4 cells was 0.17 +/- 0.02 micron/h/mg protein, similar to that of normal T4 cells, which was 0.13 +/- 0.08 micron/h/mg. The CLL T8 cells, however, had a significantly lower 5′N activity (0.17 +/- 0.02 micron/h/mg) than normal T8 cells (0.41 +/- 0.11 micron/h/mg) (P = .003). Normal null cells had very low activity, while much higher levels were found in the null cells of CLL patients whose B cells had activity. These findings document a difference in activity of an enzyme between the T8 cell population of patients with CLL and that of normal subjects.

scholarly journals Decreased 5'-nucleotidase activity in a T lymphocyte subpopulation from patients with B cell chronic lymphocytic leukemia

Blood ◽  
1984 ◽  
Vol 64 (2) ◽  
pp. 479-481 ◽  
Author(s):  
R Silber ◽  
M Conklyn
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
T Lymphocyte ◽  
Specific Activity ◽  
Normal Subjects ◽  
Lymphocyte Subpopulation ◽  
Lymphocytic Leukemia ◽  
Nucleotidase Activity ◽  
T Lymphocyte Subpopulations ◽  
Low Activity

Abstract The activity of the ectoenzyme 5′-nucleotidase (5′N) was determined in the T lymphocyte subpopulations from patients with chronic lymphocytic leukemia (CLL). 5′N could be detected only in the T cells from patients whose B cells also had enzyme activity. The specific activity of CLL T4 cells was 0.17 +/- 0.02 micron/h/mg protein, similar to that of normal T4 cells, which was 0.13 +/- 0.08 micron/h/mg. The CLL T8 cells, however, had a significantly lower 5′N activity (0.17 +/- 0.02 micron/h/mg) than normal T8 cells (0.41 +/- 0.11 micron/h/mg) (P = .003). Normal null cells had very low activity, while much higher levels were found in the null cells of CLL patients whose B cells had activity. These findings document a difference in activity of an enzyme between the T8 cell population of patients with CLL and that of normal subjects.

scholarly journals Reduced tocopherol content of B cells from patients with chronic lymphocytic leukemia

Blood ◽  
1984 ◽  
Vol 63 (1) ◽  
pp. 213-215
Author(s):  
HJ Kayden ◽  
L Hatam ◽  
MG Traber ◽  
M Conklyn ◽  
LF Liebes ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
High Performance ◽  
Mononuclear Cells ◽  
Normal Subjects ◽  
High Performance Liquid Chromatographic ◽  
Tocopherol Content ◽  
Lymphocytic Leukemia ◽  
Liquid Chromatographic Method ◽  
Liquid Chromatographic

The tocopherol content of lymphocytes, erythrocytes, and plasma from patients with chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), and normal subjects was measured by a sensitive high performance liquid chromatographic method. Lymphocytes from patients with CLL had lower values of tocopherol (1.7 +/- 1.0 micrograms/10(9) cells) than lymphocytes from normal subjects (3.8 +/- 0.7 micrograms/10(9) cells). Mononuclear cells from patients with HCL had an increased tocopherol content of 6.2 +/- 1.0 micrograms/10(9) cells. Subfractionation of the lymphocytes from patients with CLL into T- and B-cell subgroups showed that the tocopherol content of T cells was the same as in normal subjects (4.1 +/- 0.5 micrograms/10(9) cells versus 3.5 +/- 1.2), but that the tocopherol content of the B cells was markedly reduced compared to normals (2.6 +/- 1.0 versus 6.0 +/- 1.3).

scholarly journals Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population

Blood ◽  
1985 ◽  
Vol 66 (3) ◽  
pp. 614-619 ◽  
Author(s):  
R Foa ◽  
M Giovarelli ◽  
C Jemma ◽  
MT Fierro ◽  
P Lusso ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
T Lymphocytes ◽  
B Cell ◽  
T Lymphocyte ◽  
Interleukin 2 ◽  
Lymphocytic Leukemia ◽  
Ifn Gamma ◽  
Culture Supernatants

Abstract The capacity of T lymphocytes from patients with B cell chronic lymphocytic leukemia (B-CLL) to release interleukin 2 (IL 2) and interferon (IFN)-gamma was assessed following various stimuli. The spontaneous release of IL 2 and IFN-gamma was practically absent both with B-CLL and normal T lymphocytes. By contrast, after stimulation with phytohemagglutinin (PHA) or with PHA plus 12-O- tetradecanoylphorbol-13-acetate, the production of IL 2 and IFN-gamma by B-CLL T lymphocytes was similar to that of normal T lymphocytes, irrespective of the reversed T lymphocyte subset distribution (OKT4/OKT8 ratio) observed in B-CLL. However, the titer of IL 2 was greatly reduced when autologous leukemic B cells were added to the culture system. Unlike IL 2, the presence of leukemic B cells did not affect the titer of IFN-gamma in the culture supernatants. The indication that IL 2 may be adsorbed in vivo by the neoplastic B cells was further confirmed by the demonstration of the IL 2 receptor (revealed by anti-Tac monoclonal antibody) on the leukemic B cells, particularly following mitogenic stimulation, and by the evidence that exogenous IL 2 can be directly absorbed by untreated B-CLL T lymphocytes to release IFN-gamma and IL 2 is preserved, but that IL 2 may be rapidly removed by the neoplastic B-CLL cells, thus contributing to the well-documented T lymphocyte abnormalities present in this disease.

scholarly journals Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

2020 ◽  
Vol 2020 ◽  
pp. 1-12 ◽  
Author(s):  
L. Karabon ◽  
A. Partyka ◽  
L. Ciszak ◽  
E. Pawlak-Adamska ◽  
A. Tomkiewicz ◽  
...  
Keyword(s):  
T Cells ◽  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
T Lymphocyte ◽  
Immune Checkpoint ◽  
Cell Activation ◽  
Cell Function ◽  
Lymphocytic Leukemia ◽  
Gene Transcript

Chronic lymphocytic leukemia (CLL) is characterized by the peripheral accumulation of neoplastic B cells and is frequently complicated by the systemic immunosuppression associated with an impairment in B and T lymphocyte activation. We hypothesized that the expression of immune checkpoint suppressors B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte antigen (CTLA-4) is disturbed in both lymphocyte subpopulations in CLL. The expression of CTLA-4 and BTLA mRNA was determined by real-time PCR, while CTLA-4 protein expression (surface or intracellular) was estimated in BTLA+ lymphocytes by flow cytometry. In CLL patients, we observed a higher gene transcript level of BTLA and CTLA-4 than in healthy individuals in both freshly isolated and PMA stimulated B and T cells. Remarkably, lower amounts of both inhibitory proteins were found in peripheral blood (PB) CLL B cells, whereas normal BTLA and elevated CTLA-4 were found in T cells. Consistently, there was a prevalence of CTLA-4+ cells within circulating BTLA+ T cells cells of patients confronting PB healthy cells. After in vitro stimulation, the only change found in CLL patients was a decrease in BTLA expression in B and T lymphocytes. In contrast, healthy lymphocytes responded more vigorously as regards the BTLA and CTLA expression with substantially higher frequency of CD69+ cells under the stimulating condition compared to corresponding cells from the CLL group. Our results indicate that CLL development is associated with the affected expression of BTLA and CTLA-4 checkpoint receptors in PB and its impaired expression might be associated with lowering of the threshold for B cell activation and proliferation, while upregulated CTLA-4 expression in CLL peripheral BTLA+ T cells may contribute to suppressed T cell effector functions. This hypothesis needs to be validated in future studies, which would allow us to explain how the increased or decreased expression of these molecules affects the cell function.

scholarly journals Reduced tocopherol content of B cells from patients with chronic lymphocytic leukemia

Blood ◽  
1984 ◽  
Vol 63 (1) ◽  
pp. 213-215 ◽  
Author(s):  
HJ Kayden ◽  
L Hatam ◽  
MG Traber ◽  
M Conklyn ◽  
LF Liebes ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
High Performance ◽  
Mononuclear Cells ◽  
Normal Subjects ◽  
High Performance Liquid Chromatographic ◽  
Tocopherol Content ◽  
Lymphocytic Leukemia ◽  
Liquid Chromatographic Method ◽  
Liquid Chromatographic

Abstract The tocopherol content of lymphocytes, erythrocytes, and plasma from patients with chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), and normal subjects was measured by a sensitive high performance liquid chromatographic method. Lymphocytes from patients with CLL had lower values of tocopherol (1.7 +/- 1.0 micrograms/10(9) cells) than lymphocytes from normal subjects (3.8 +/- 0.7 micrograms/10(9) cells). Mononuclear cells from patients with HCL had an increased tocopherol content of 6.2 +/- 1.0 micrograms/10(9) cells. Subfractionation of the lymphocytes from patients with CLL into T- and B-cell subgroups showed that the tocopherol content of T cells was the same as in normal subjects (4.1 +/- 0.5 micrograms/10(9) cells versus 3.5 +/- 1.2), but that the tocopherol content of the B cells was markedly reduced compared to normals (2.6 +/- 1.0 versus 6.0 +/- 1.3).

scholarly journals Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population

Blood ◽  
1985 ◽  
Vol 66 (3) ◽  
pp. 614-619 ◽  
Author(s):  
R Foa ◽  
M Giovarelli ◽  
C Jemma ◽  
MT Fierro ◽  
P Lusso ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
T Lymphocytes ◽  
B Cell ◽  
T Lymphocyte ◽  
Interleukin 2 ◽  
Lymphocytic Leukemia ◽  
Ifn Gamma ◽  
Culture Supernatants

The capacity of T lymphocytes from patients with B cell chronic lymphocytic leukemia (B-CLL) to release interleukin 2 (IL 2) and interferon (IFN)-gamma was assessed following various stimuli. The spontaneous release of IL 2 and IFN-gamma was practically absent both with B-CLL and normal T lymphocytes. By contrast, after stimulation with phytohemagglutinin (PHA) or with PHA plus 12-O- tetradecanoylphorbol-13-acetate, the production of IL 2 and IFN-gamma by B-CLL T lymphocytes was similar to that of normal T lymphocytes, irrespective of the reversed T lymphocyte subset distribution (OKT4/OKT8 ratio) observed in B-CLL. However, the titer of IL 2 was greatly reduced when autologous leukemic B cells were added to the culture system. Unlike IL 2, the presence of leukemic B cells did not affect the titer of IFN-gamma in the culture supernatants. The indication that IL 2 may be adsorbed in vivo by the neoplastic B cells was further confirmed by the demonstration of the IL 2 receptor (revealed by anti-Tac monoclonal antibody) on the leukemic B cells, particularly following mitogenic stimulation, and by the evidence that exogenous IL 2 can be directly absorbed by untreated B-CLL T lymphocytes to release IFN-gamma and IL 2 is preserved, but that IL 2 may be rapidly removed by the neoplastic B-CLL cells, thus contributing to the well-documented T lymphocyte abnormalities present in this disease.

Sign in / Sign up

Export Citation Format

Share Document